Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Theodore L. Crandall"'
Autor:
Shannon Stockton, Paul Catalano, Steven J Cohen, Barbara A Burtness, Edith P Mitchell, Efrat Dotan, Sam J Lubner, Pankaj Kumar, Mary F Mulcahy, George A Fisher, Theodore L Crandall, Al Benson
Publikováno v:
The Oncologist.
Background Patients with advanced esophageal cancer carry poor prognoses; limited data exist to guide second-line therapy in the metastatic setting. Paclitaxel has been used yet is associated with limited efficacy. There is preclinical evidence of sy
Autor:
Marwan Fakih, Nathan Bahary, Amy Schmotzer, Ramesh K. Ramanathan, Theodore L. Crandall, Ronald G. Stoller, Stewart L. Lancaster, R. A. Pinkerton, Douglas M. Potter, Barry C. Lembersky, Benedito A. Carneiro, Smitha S. Krishnamurthi
Publikováno v:
Clinical colorectal cancer. 11(1)
Background Irinotecan and weekly cetuximab (I+C) is a standard second-line regimen for metastatic colorectal cancer (mCRC). This study investigated the safety and efficacy of every 2 weeks I+C in patients with mCRC. Patients and Methods Patients with
Autor:
J. Franklin Viverette, Mohammad Abbas, Vida Almario Passero, John K. Waas, Ryan Kennedy, Markus Y. Mapara, Anastasios Raptis, Jennifer L. Osborn, Min Sun, Amy K. O’Sullivan, Terry Evans, Jing-Zhou Hou, Diane Gardner, G. David Roodman, Theodore L. Crandall, Suzanne Lentzsch, Daniel Petro, Robert L. Redner, Lijun Dai, Robert Volkin, Daniel P. Normolle, Carrie Andreas, L. Pietragallo, Ronald Fierro, Vincent Reyes, Yongli Shuai, Stanley M. Marks, R. A. Pinkerton
Publikováno v:
Blood. 118:4142-4142
Abstract 4142 Introduction: High dose chemotherapy combined with autologous stem cell transplantation (ASCT) as opposed to conventional chemotherapy improved progression free survival (PFS) and overall survival (OS) in multiple myeloma (MM) and is cu
Autor:
Ramesh K. Ramanathan, Rajesh Sehgal, D.M. Potter, R. A. Pinkerton, B.C. Lembersky, K. K. Rajasenan, Theodore L. Crandall, Edward P. Balaban, P. Kane
Publikováno v:
European Journal of Cancer Supplements. 7:339
Autor:
Smitha S. Krishnamurthi, R. A. Pinkerton, Marwan Fakih, S. Lancaster, B. A. Carneiro, Theodore L. Crandall, Douglas M. Potter, Barry C. Lembersky, Nathan Bahary, Ramesh K. Ramanathan
Publikováno v:
Journal of Clinical Oncology. 27:e15088-e15088
e15088 Background: I + C is a standard second line mCRC regimen. Our study investigated the efficacy and safety of a biweekly I + C combination in patients (pts) with mCRC. Methods: mCRC pts who failed 1st line fluoropyrimidine/oxaliplatin regimens a
Autor:
Theodore L. Crandall, Ramesh K. Ramanathan, C. Kinney, R. A. Pinkerton, Douglas M. Potter, P. Kane, Edward P. Balaban, Rajesh Sehgal, K. K. Rajasenan, Barry C. Lembersky
Publikováno v:
Journal of Clinical Oncology. 26:4061-4061
4061 Background: CapOx and Bev is becoming a standard regimen for advanced CRC utilizing Cap on a d 1–14 schedule every 3 wks. However optimal doses and schedules of Cap with Ox and Bev needs continued evaluation. Intermittent wkly Cap (3,500 mg/m2
Autor:
Marwan Fakih, R. A. Pinkerton, Barry C. Lembersky, Ramesh K. Ramanathan, Nathan Bahary, S. Lancaster, Amy Schmotzer, Theodore L. Crandall, Alok A. Khorana, Smitha S. Krishnamurthi
Publikováno v:
Journal of Clinical Oncology. 26:15050-15050
15050 Background: I + C is a standard second line regimen for pts treated with 5-flurouracil, oxaliplatin and bevacizumab in the US. Second line therapy with I + C results in a response rate (RR) o...
Autor:
S. Dranko, Douglas M. Potter, Barry C. Lembersky, Edward P. Balaban, K. K. Rajasenan, Theodore L. Crandall, Ramesh K. Ramanathan, Amy Schmotzer, P. Kane, R. A. Pinkerton
Publikováno v:
Journal of Clinical Oncology. 25:4092-4092
4092 Background: FOLFOX in combination with Bev is a standard regimen for treating advanced CRC. Cap on a d 1–14 schedule every 3 weeks is now being substituted for 5-flurouracil (CapOx); however optimal doses and schedules of Cap in combination wi
Publikováno v:
Blood. 104:4402-4402
The treatment of elderly patients with acute myelogeneous leukemia is quite difficult primarily due to the treatment related morbidity and the poor response rate to induction chemotherapy. Elderly patients are often offered supportive care only. Mylo